Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended – which means compounding of the medicine must stop.

Popular weight-loss medications including Ozempic and Wegovy contain a drug that seems to decrease cravings for food and drugs – and now there’s evidence that it might make exercise less rewarding, to

Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance plans, a new survey shows.

When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound, only a fifth of large U.S. companies cover the medications in their health insurance plans, a new survey shows. In a report published Wednesday in the journal Health Affairs,

Less than a fifth of large employers in the U.S. include coverage for the popular but pricey weight loss drugs Wegovy and Zepbound, a KFF survey finds.

But FDA says it's over. Compounding pharmacies are suing the Food and Drug Administration so they can keep making imitation versions of popular—and lucrative—tirzepatide drugs, namely knockoffs of Mounjaro for diabetes and Zepbound for weight loss.

With the shortage over, compounding pharmacies are no longer allowed to produce the popular weight loss drugs.